![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Persistence of Resistance-Associated Variants in Hepatitis C Virus (HCV) Genotype 1-4 Infected Subjects Following 3-day Samatasvir Monotherapy
|
|
|
Reported by Jules Levin
International Workshop on Antiviral Drug Resistance, June 3-7, 2014 in Berlin, Germany
B Heinrich1, B Vince2, JM Hill3, EJ Lawitz4, W O'Riordan5, LR Webster6, DM Gruener7, RS Mofsen8, A Murillo9, J Chen1, JF McCarville1, K Pietropaolo1, JP Bilello1, L Sweeney1, M Seifer1 and D Mayers1
1 Idenix Pharmaceuticals, Inc., Cambridge, MA, USA; 2 Vince and Associates Clinical Research, Overland Park, KS, USA; 3 Avail Clinical Research, DeLand, FL, USA; 4 Alamo Medical Research, San Antonio, TX, USA;
5 eStudySite, San Diego, CA, USA; 6 CRI Lifetree Clinical Research, Salt Lake City, UT, USA; 7 CRI Worldwide, Philadelphia, PA, USA; 8 St. Louis Clinical Trials, St. Louis, MO, USA; and 9 AMPM Research Clinic, Miami, FL, USA.
![Resist1.gif](../images/060914/060914-7/Resist1.gif)
![Resist2.gif](../images/060914/060914-7/Resist2.gif)
![Resist3.gif](../images/060914/060914-7/Resist3.gif)
![Resist4.gif](../images/060914/060914-7/Resist4.gif)
![Resist5.gif](../images/060914/060914-7/Resist5.gif)
![Resist6.gif](../images/060914/060914-7/Resist6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|